Latest News about JNJ
Recent news which mentions JNJ
Cancer Drugs Propel J&J Beyond Wall Street Estimates
October 15, 2024
From Benzinga
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
October 15, 2024
Tickers
JNJ
From Motley Fool
From Benzinga
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
October 15, 2024
From Benzinga
From Benzinga
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
October 15, 2024
From Benzinga
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
October 15, 2024
From Benzinga
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
October 15, 2024
From Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
October 14, 2024
From Benzinga
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
October 14, 2024
From Benzinga
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
October 14, 2024
From Benzinga
Columbus Day: Is Stock Market Open Today?
October 14, 2024
From Benzinga
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
October 13, 2024
From Motley Fool
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
From Benzinga
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
October 10, 2024
From Benzinga
1 Vanguard Index Fund Could Turn $500 Per Month Into a $968,400 Portfolio That Pays $16,000 in Annual Dividend Income
October 09, 2024
From Motley Fool
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
October 08, 2024
From Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
October 04, 2024
From Benzinga
2 Smart Income Stocks to Buy Right Now
October 04, 2024
From Motley Fool
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
October 02, 2024
From Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
September 30, 2024
From Benzinga
2 Excellent Dividend Stocks to Buy With Less Than $200
September 28, 2024
From Motley Fool
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
September 27, 2024
From Benzinga
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
September 26, 2024
From Benzinga
Why Masimo Stock Crushed the Market Today
September 25, 2024
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.